Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03QWO
|
|||
| Former ID |
DCL000771
|
|||
| Drug Name |
Dexefaroxan
|
|||
| Synonyms |
Dexefaroxan [INN]; (+)-(r)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline; 2-[(2R)-2-ethyl-3H-1-benzofuran-2-yl]-4,5-dihydro-1H-imidazole
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Phase 2 | [1] | |
| Schizophrenia [ICD-11: 6A20] | Discontinued in Phase 2 | [2] | ||
| Company |
Pierre Fabre
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H16N2O
|
|||
| Canonical SMILES |
CCC1(CC2=CC=CC=C2O1)C3=NCCN3
|
|||
| InChI |
1S/C13H16N2O/c1-2-13(12-14-7-8-15-12)9-10-5-3-4-6-11(10)16-13/h3-6H,2,7-9H2,1H3,(H,14,15)/t13-/m1/s1
|
|||
| InChIKey |
RATZLMXRALDSJW-CYBMUJFWSA-N
|
|||
| CAS Number |
CAS 143249-88-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A2a receptor (ADORA2A) | Target Info | Agonist | [2] |
| Nicotinic acetylcholine receptor (nAChR) | Target Info | Agonist | [2] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Calcium signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Parkinson's disease | ||||
| Alcoholism | ||||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | |||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| Reactome | NGF-independant TRKA activation | |||
| Adenosine P1 receptors | ||||
| G alpha (s) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Nucleotide GPCRs | |||
| Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| NGF signalling via TRKA from the plasma membrane | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Effects of the alpha 2-adrenoreceptor antagonist dexefaroxan on neurogenesis in the olfactory bulb of the adult rat in vivo: selective protection against neuronal death. Neuroscience. 2003;117(2):281-91. | |||
| REF 2 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.